Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 01, 2015 3:32 AM ET


Company Overview of Salix Pharmaceuticals Ltd.

Company Overview

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides Xifaxan tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; Apriso to maintain remission of ulcerative colitis (UC); Moviprep and Osmoprep for cleansing of the colon as a preparation for colonoscopy in adults; Relistor for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; Solesta to treat fecal incontinence; and Deflux to treat vesicoureteral reflux. It also offers Fulyzaq for the symptomatic relief of non-infectious diarrhea in adult...

8510 Colonnade Center Drive

Raleigh, NC 27615

United States

Founded in 1989

1,000 Employees





Key Executives for Salix Pharmaceuticals Ltd.

Founder and Chief Scientific Liaison
Age: 60
General Counsel, Executive Vice President, Secretary and Director
Age: 45
Associate Vice President of Investor Relations & Corporate Communications
Compensation as of Fiscal Year 2015.

Salix Pharmaceuticals Ltd. Key Developments

RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals

RedHill Biopharma Ltd. has provided an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals Ltd., recently acquired by Valeant Pharmaceuticals International Inc. Salix confirmed to RedHill that it continues the development of RHB-106. Salix further clarified to RedHill that the bowel purgative product referenced in Valeant's second quarter 2015 financial results presentation1 as a failed toxicology screen is not RedHill's RHB-106. RHB-106 is an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests such as colonoscopies, barium enemas or virtual colonoscopies, as well as surgical interventions, such as laparotomies. RHB-106 is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side effects and improved compliance. It is also intended to prevent patient exposure to the often unappealing taste of current products.

Valeant Pharmaceuticals International, Inc. Plans to Lay Off 258 Salix Workers

Valeant announced plans to lay off 258 Salix workers the day after it closed the acquisition. Salix executives received $78 million in golden parachute payments.

Salix Pharmaceuticals Ltd.(NasdaqGM:SLXP) dropped from Russell 1000 Index

Salix Pharmaceuticals Ltd. will be removed from Russell 1000 Index.

Similar Private Companies By Industry

Company Name Region
Rhodes Technologies Inc. United States
Drais Pharmaceuticals, Inc. United States
Hera Biomedical, Inc. United States
Herbal Nurse, Inc. United States
Merial Limited United States

Recent Private Companies Transactions

March 11, 2015
February 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Salix Pharmaceuticals Ltd., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at